Jack Bendheim, President and CEO of Phibro Animal Health Corporation (NASDAQ:PAHC), disclosed the indirect sale of 18,608 shares of Common Stock across multiple open-market transactions from May 5, 2026 through May 7, 2026, as reported in the SEC Form 4 filing.
Transaction summary
|
Metric |
Value |
|---|---|
|
Shares sold (indirect) |
18,608 |
|
Transaction value |
$1.0 million |
|
Post-transaction shares (direct) |
16,840 |
|
Post-transaction shares (indirect) |
56,152 |
|
Post-transaction value (direct ownership) |
~$727K |
Transaction value based on SEC Form 4 weighted average purchase price ($54.61); post-transaction value based on total reported shares multiplied by the final May 7, 2026 close price, as calculated in SEC data.
Key questions
-
How material was the reduction in indirect ownership from this sale?
This sale accounted for 24.89% of Jack Bendheim’s indirect holdings, reducing his indirect position via BFI Co. LLC from 74,760 shares to 56,152 shares as of May 7, 2026. -
What trading plan governed these transactions?
These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025 -
How do these trades compare to Bendheim’s historical activity?
Since January 2026, trade sizes have remained within the typical historical range for Bendheim, with the most recent sales reflecting a reduction in capacity as total reported holdings fell by 96.77% from 520,712 to 16,840 shares over the “recent” period. -
Does Bendheim maintain a material ownership stake after this transaction?
Despite this disposition, Bendheim continues to have exposure through 16,840 directly held shares, 56,152 shares held indirectly, and a total of 449,485 Class A Common Stock shares (direct and indirect), which are convertible into Common Stock, preserving meaningful economic alignment.
Company overview
|
Metric |
Value |
|---|---|
|
Revenue (TTM) |
$1.50 billion |
|
Net income (TTM) |
$95.23 million |
|
Dividend yield |
1.88% |
|
1-year price change |
50.21% |
* 1-year performance calculated using May 7th, 2026 as the reference date.
Company snapshot
-
PAHC produces and markets animal health products, nutritional specialties, vaccines, and mineral nutrition solutions for livestock, including poultry, swine, cattle, and aquaculture.
-
The company generates revenue primarily through the sale of proprietary and generic pharmaceuticals, nutritional additives, and specialty ingredients to the commercial animal agriculture sector.
-
It serves integrated poultry, swine, and cattle producers, as well as animal feed manufacturers, wholesalers, and distributors across the United States and international markets.
